U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H23N7O6
Molecular Weight 457.4399
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARFOLITIXORIN

SMILES

NC1=NC(=O)C2=C(NC[C@@H]3CN(CN23)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1

InChI

InChIKey=QYNUQALWYRSVHF-OLZOCXBDSA-N
InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12-,13+/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H23N7O6
Molecular Weight 457.4399
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

METHYLENETETRAHYDROFOLIC ACID, L-(+), an endogenous biomodulator that was developed under the brand name modufolin or arfolitixorin by the Isofol Medical. Arfolitixorin is developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. This drug is currently being studied in a global phase 3 clinical trial. Besides, the drug successfully completed phase II as rescue therapy for osteosarcoma. 21 May 2019 Isofol Medical has received clinical patent protection for the arfolitixorinin USA. It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2860 ng/mL
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4410 ng/mL
60 mg/m² single, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
21200 ng/mL
240 mg/m² single, intravenous
dose: 240 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
39.4 pmol/mL
416 μg/m² single, intravenous
dose: 416 μg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1460 ng × h/mL
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2370 ng × h/mL
60 mg/m² single, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10600 ng × h/mL
240 mg/m² single, intravenous
dose: 240 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
210 pmol × h/mL
416 μg/m² single, intravenous
dose: 416 μg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: FLUOROURACIL
METHYLENETETRAHYDROFOLIC ACID, L-( )- plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Molecular biology of 5,10-methylenetetrahydrofolate reductase.
2000 Jan-Feb
Formaldehyde-detoxifying role of the tetrahydromethanopterin-linked pathway in Methylobacterium extorquens AM1.
2003 Dec
Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
2015 Oct

Sample Use Guides

IV injection every second week for 8 weeks 30 to 240 mg/m2
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:34:58 GMT 2025
Edited
by admin
on Mon Mar 31 21:34:58 GMT 2025
Record UNII
Z8R4A37V9Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MODUFOLIN
Preferred Name English
ARFOLITIXORIN
USAN   INN  
Official Name English
ARFOLITIXORIN [USAN]
Common Name English
(6R)-5,10-METHYLENETETRAHYDROFOLATE
Common Name English
6R-MTHF
Common Name English
D-N5,N10-METHYLENE-L-TETRAHYDROFOLIC ACID
Common Name English
5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID
Common Name English
(6R)-5,10-METHYLENE-5,6,7,8-TETRAHYDROFOLIC ACID
Common Name English
Arfolitixorin [WHO-DD]
Common Name English
METHYLENETETRAHYDROFOLIC ACID, L-(+)-
Common Name English
ISO-901
Code English
L-(+)-METHYLENETETRAHYDROFOLIC ACID
Common Name English
arfolitixorin [INN]
Common Name English
N-(4-((6AR)-3-AMINO-1-OXO-1,2,5,6,6A,7-HEXAHYDROIMIDAZO(1,5-F)PTERIDIN-8(9H)- YL)BENZOYL)-L-GLUTAMIC ACID
Systematic Name English
L-GLUTAMIC ACID, N-(4-((6AR)-3-AMINO-1,2,5,6,6A,7-HEXAHYDRO-1-OXOIMIDAZO(1,5-F)PTERIDIN-8(9H)-YL)BENZOYL)-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 189304
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID60185584
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
CHEBI
1989
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
DRUG BANK
DB12676
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
INN
10689
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
SMS_ID
100000178228
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
USAN
FG-126
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
NCI_THESAURUS
C157079
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
FDA UNII
Z8R4A37V9Q
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
CAS
31690-11-6
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
PUBCHEM
135398645
Created by admin on Mon Mar 31 21:34:58 GMT 2025 , Edited by admin on Mon Mar 31 21:34:58 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY